Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

This study tests a combination of two targeted drugs — vebreltinib (a MET inhibitor) and PLB1004 (an EGFR inhibitor) — as first-line treatment for people with advanced non-small cell lung cancer (NSCLC) that has two specific molecular changes: an EGFR mutation and MET overexpression. These genetic changes make the cancer sensitive to this combination. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic NSCLC (stage IIIB–IV) confirmed by biopsy - Your cancer has a specific EGFR mutation (exon 19 deletion or L858R) - Your cancer also has MET overexpression (IHC 3+) - You have not received any prior systemic treatment for your lung cancer - Your performance status is ECOG 0–1 **You may NOT be eligible if...** - Your cancer has ALK or ROS1 mutations (different targets) - You have unstable brain metastases requiring steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.